Lung Cancer (SCLC)

    Genetic Abnormality Prevalence Clinical Experience with Targeted Agent
    DLL3 Rovalpituzumab tesirine (anti-DLL3 ADC):
    • Phase 1: RR 18% of all pts, RR 38% in DLL3+ pts; PFS 2.8 mo for all pts, PFS 4.3 mo for DLL3+ pts vs. 2.2 mo for DLL3− pts (31)
    PARP N/A Veliparib (PARP inhibitor):
    • Phase 2, with temozolomide: ORR 39% veliparib + TMZ vs. 14% placebo + TMZ; OS 8.2 mo veliparib + TMZ vs. 7 mo placebo + TMZ (32)
    • Phase 2, with cisplatin + etoposide: PFS 6.1 mo for V vs. 8.9 mo for CE + P (33)
    Other topics in Targets by Organ Site